Aeglea BioTherapeutics In... (AGLE)
NASDAQ: AGLE
· Real-Time Price · USD
12.01
0.75 (6.66%)
At close: Nov 27, 2023, 10:00 PM
Aeglea BioTherapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -44.77M | 67.59M | -69.03M | -38.84M | -40.11M | -217.08M | -18.42M | -18.82M | -18.23M | -22.32M | -24.44M | -20.45M | -20.31M | -6.83M | -18.22M |
Depreciation & Amortization | n/a | -12.37M | n/a | n/a | n/a | 580K | 384K | 385K | 401K | 378K | 403K | 411K | 412K | 398K | 355K |
Stock-Based Compensation | 8.86M | 36.43M | 13.1M | 8.68M | 4.79M | 1.91M | 1.71M | 1.43M | 1.57M | 2.02M | 2.1M | 2.09M | 2.11M | 2.08M | 1.76M |
Other Working Capital | n/a | 4.34M | 28.02M | -7.77M | -6.91M | 5.31M | -2.75M | 2.34M | -1.08M | -53K | -4.07M | -2.97M | 830K | 6.07M | -3.16M |
Other Non-Cash Items | n/a | 8.6M | 824K | -28.62M | 8.68M | -160K | 59K | 28K | 68K | 88K | 96K | 186K | 293K | 44K | 115K |
Deferred Income Tax | n/a | -192.13M | n/a | n/a | n/a | 192.13M | n/a | n/a | n/a | 234K | -18K | 88K | 180K | -71K | 7K |
Change in Working Capital | n/a | 3.34M | 25.68M | -3.47M | -7.95M | 5.97M | -1.36M | -1.16M | 1.13M | -1.07M | -4.41M | -1.51M | 495K | 6.39M | -3.54M |
Operating Cash Flow | -40.99M | -88.54M | -29.42M | -62.25M | -34.6M | -16.64M | -17.63M | -18.14M | -15.07M | -20.67M | -26.26M | -19.27M | -17M | 2.08M | -19.53M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -1K | n/a | -37K | n/a | -93K | -30K | -450K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -71.44M | -486.62M | -35.05M | -178.39M | -112.63M | n/a | n/a | -4.5M | -7.25M | -24.25M | -3.5M | -13.25M | -26.25M | -69.33M | -24.25M |
Sales Maturities Of Investments | 71.38M | 224.97M | 77.79M | 57.88M | n/a | 3.25M | 17.75M | 18.5M | 23.75M | 25M | 29.3M | 22.91M | 32.12M | 22M | 34M |
Other Investing Acitivies | n/a | -18.51M | n/a | n/a | 15M | 3.51M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -61K | -280.16M | 42.74M | -120.52M | -97.63M | 6.76M | 17.75M | 14M | 16.5M | 750K | 25.76M | 9.66M | 5.78M | -47.36M | 9.3M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 125K | 44.6M | 17.89M | 4.88M | -12.53M | 209.99M | 10K | -8K | -130K | 42.8M | 12K | 80K | 1.14M | -192K | 362K |
Financial Cash Flow | 125K | 213.44M | 12.78M | 360K | -12.53M | 209.99M | 10K | -8K | -130K | 42.8M | 12K | 80K | 1.14M | -192K | 362K |
Net Cash Flow | -40.93M | n/a | 26.44M | -182.09M | -144.78M | 200.12M | 137K | -4.1M | 1.24M | 22.81M | -515K | -9.52M | -10.11M | -45.47M | -9.86M |
Free Cash Flow | -40.99M | -88.54M | -29.42M | -62.25M | -34.6M | -16.64M | -17.63M | -18.14M | -15.07M | -20.67M | -26.3M | -19.27M | -17.09M | 2.05M | -19.98M |